Personalized Therapy Arrives for Patients with Colorectal Cancer

摘要

Earlier this year the American Society of Clinical Oncology (ASCO) offered as a "provisional clinical opinion" the statement that "all patients with metastatic colon cancer should have their tumors tested for KRAS mutations" (J. Clin. Oncol, 27[12]: 2091-6, 2009). Others have said much the same thing-for example, it should be "standard practice" to restrict colon-cancer treatment targeted at the epidermal growth factor receptor (EGFR) to patients whose tumors test positive for wild-type (non-mutated) KRAS (D.Z. Chang, et at, J. Hematol Oncol, 2:18, 2009).